Table 3 Antidiabetic Drug use, by maternal age, in all livebirth pregnancies during 2001–2013 in the MSDD
|  | < 20 years | 20–24 years | 25–29 years | 30–34 years | 35–39 years | 40–44 years | 45–54 years |
|---|---|---|---|---|---|---|---|
Total unique pregnancies | 115,584 (100%) | 260,013 (100%) | 495,250 (100%) | 610,703 (100%) | 329,080 (100%) | 76,995 (100%) | 7979 (100%) |
Drug product/Class | |||||||
 Any Antidiabetic Drug | 1004 (0.87%) | 5227 (2.01%) | 18,775 (3.79%) | 30,327 (4.97%) | 20,788 (6.32%) | 5874 (7.63%) | 681 (8.53%) |
 Alpha-Glucosidase Inhibitors | 4 (0.00%) | 10 (0.00%) | 31 (0.01%) | 54 (0.01%) | 30 (0.01%) | 18 (0.02%) | 2 (0.03%) |
 Amylin Analog | 1 (0.00%) | 4 (0.00%) | 15 (0.00%) | 19 (0.00%) | 6 (0.00%) | 3 (0.00%) | 0 (0.00%) |
 Metformin | 294 (0.25%) | 1839 (0.71%) | 8616 (1.74%) | 12,809 (2.10%) | 7238 (2.20%) | 1687 (2.19%) | 274 (3.43%) |
 Dipeptidyl Peptidase-4 Inhibitors | 1 (0.00%) | 4 (0.00%) | 34 (0.01%) | 69 (0.01%) | 83 (0.03%) | 30 (0.04%) | 21 (0.26%) |
 Glucagon-like Peptide-1 Receptor Agonists | 4 (0.00%) | 12 (0.00%) | 58 (0.01%) | 109 (0.02%) | 98 (0.03%) | 36 (0.05%) | 16 (0.20%) |
 Meglitinide Analogs | 1 (0.00%) | 8 (0.00%) | 8 (0.00%) | 13 (0.00%) | 9 (0.00%) | 3 (0.00%) | 2 (0.03%) |
 Sulfonylureas | 237 (0.21%) | 1452 (0.56%) | 5542 (1.12%) | 10,151 (1.66%) | 8012 (2.43%) | 2570 (3.34%) | 276 (3.46%) |
 Thiazolidinediones | 17 (0.01%) | 69 (0.03%) | 208 (0.04%) | 268 (0.04%) | 196 (0.06%) | 73 (0.09%) | 43 (0.54%) |
 Combination Products | 10 (0.01%) | 55 (0.02%) | 117 (0.02%) | 197 (0.03%) | 177 (0.05%) | 52 (0.07%) | 25 (0.31%) |
 Insulin | 590 (0.51%) | 2562 (0.99%) | 6986 (1.41%) | 11,868 (1.94%) | 9392 (2.85%) | 2813 (3.65%) | 265 (3.32%) |